F. Di Raimondo

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
F Di Raimondo, F. Di Raimondo, Francesco Di Raimondo
Publication record
377 papers · 16,422 citations · H-index 63

PAPERS

Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience
20243 citationsauthor #24
MACROH2A1.1 SITS AT THE INTERPLAY BETWEEN EPIGENETICS AND INFLAMMATION OF MESENCHYMAL STROMAL CELLS IN MYELODYSPLASTIC SYNDROMES
20230 citationsauthor #17
Efficacy and safety of tixagevimab‐cilgavimab versus SARS‐CoV‐2 breakthrough infection in the hematological conditions
202316 citationsauthor #14
Lenalidomide plus Dexamethasone Combination as First-Line Oral Therapy of Multiple Myeloma Patients: A Unicentric Real-Life Study
20236 citationsauthor #11
P59 ACTIVE TREATMENT AND LOW IGM ARE ASSOCIATED WITH INFERIOR SARS-COV-2 SPIKE ANTIBODY RESPONSE TO THREE DOSES OF COVID-19 RNA VACCINATION IN PATIENTS WITH MULTIPLE MYELOMA
20230 citationsauthor #12
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab
202314 citationsauthor #12
POSTER: IBCL-057 Incidence and Features of SARS-CoV-2 Breakthrough Infection in the Hematological Conditions After Tixagevimab-Cilgavimab Prophylaxis
20230 citationsauthor #15
PB1993: EXPRESSION OF NEO-201 MAY HELP IN THE DIFFERENTIAL DIAGNOSIS BETWEEN MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
20230 citationsauthor #8
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine
202315 citationsauthor #10
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study
202318 citationsauthor #27
P60 EVOLVING OUTCOMES OF EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA: 20-YEARS SINGLE CENTER EXPERIENCE
20232 citationsauthor #9
P21 EFFECTIVENESS AND SAFETY OF DELAYED BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE (VTD) REGIMEN
20230 citationsauthor #8
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials
202315 citationsauthor #44
P594: THE CXCR4-LOW/CD5-HIGH PROLIFERATIVE FRACTION IS ENRICHED IN BTK MUTATIONS AND ANTICIPATES RELAPSE IN IBRUTINIB-TREATED CLL
20230 citationsauthor #13
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases
20234 citationsauthor #11
Multicentric Castleman Disease and Concurrent Hematological Disorders: The Occurrence of Plasmacytoma and the Hypotheses Arising from Literature Review
20230 citationsauthor #8
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia
20230 citationsauthor #16
Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno‐microenvironment in multiple myeloma
202319 citationsauthor #16
Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance Data
202311 citationsauthor #15
AIPSS‐MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib
20234 citationsauthor #4
Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future
202322 citationsauthor #9
P02 ARGININE DEPRIVATION INDUCES ACQUISITION OF A SENESCENT PHENOTYPE AND FAVORS GENOMIC INSTABILITY IN MULTIPLE MYELOMA PLASMACELLS
20230 citationsauthor #20
PB2072: CIRCULATING CD71+ MYELOID PRECURSORS IN MGUS AND MULTIPLE MYELOMA: A PROSPECTIVE SURVEY
20230 citationsauthor #8
PB2093: OVERALL SURVIVAL IN RELAPSED-REFRACTORY MYELOMA PATIENTS DEPENDS ON CIRCULATING PLASMA CELLS QUANTITATION
20230 citationsauthor #6
A case of high‐risk AML in a patient with advanced systemic mastocytosis
20238 citationsauthor #14
Primary Mediastinal B‐cell Lymphoma, a nationwide real‐life retrospective study from Fondazione Italiana Linfomi (FIL)
20230 citationsauthor #36
P535: UPDATES FROM ITALIAN MULTICENTER REAL-LIFE EXPERIENCE ON CPX-351 THERAPY IN YOUNG PATIENTS (<60 YEARS OLD).
20221 citationsauthor #21
Preclinical evidence of a direct pro-survival role of arginine deprivation in multiple myeloma
20226 citationsauthor #5
P931: PROSPECTIVE OBSERVATIONAL MULTICENTER STUDY OF GAUCHER DISEASE PREVALENCE IN PATIENTS AFFECTED BY MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE
20220 citationsauthor #24
Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel
202238 citationsauthor #5
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment
202236 citationsauthor #19
P596: CLINICAL IMPACT OF TP53 DISRUPTION IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH A BCR INHIBITOR. A CAMPUS CLL EXPERIENCE
20221 citationsauthor #25
Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection
20225 citationsauthor #14
Hedgehog signaling pathways in multiple myeloma
20220 citationsauthor #15
P893: CARFILZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (KRD) AS SALVAGE THERAPY FOR MULTIPLE MYELOMA PATIENTS: ITALIAN, MULTICENTER, RETROSPECTIVE EXPERIENCE OUTSIDE OF CLINICAL TRIALS
20220 citationsauthor #27
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials
20224 citationsauthor #44
T-Cell Lymphocyte Kinetics As a Predictive Biomarker of Blinatumomab MRD Response in ALL-B Patients: A Single-Center Prospective Study
20220 citationsauthor #11
Relapse of immune-mediated thrombotic thrombocytopenic purpura following mRNA COVID-19 vaccination: a prospective cohort study
202217 citationsauthor #10
Pegylated Asparaginase‐Induced Liver Injury: A Case‐Based Review and Data From Pharmacovigilance
20226 citationsauthor #15
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials
202212 citationsauthor #51
The CXCR4dim/CD5bright Proliferative Fraction Reappears in Relapsed CLL Under Ibrutinib, Enriched in BTK Mutations
20220 citationsauthor #11
PB1984: ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED 3-YEAR FOLLOW-UP OF AN ITALIAN, MULTICENTER, EXPERIENCE OUTSIDE OF CONTROLLED CLINICAL TRIALS
20220 citationsauthor #51
VEXAS-like syndrome: a potential new entity?
20224 citationsauthor #4
Saprochete capitata: Emerging Infections from Uncommon Microorganisms in Hematological Diseases
20228 citationsauthor #10
P988: LACTATE RESHAPES TUMOR MICROENVIRONMENT AND METABOLIC PROFILE IN MYELOFIBROSIS
20220 citationsauthor #16
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients
20223 citationsauthor #10
Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field
202221 citationsauthor #11
Label-Free Enrichment of Circulating Tumor Plasma Cells: Future Potential Applications of Dielectrophoresis in Multiple Myeloma
20224 citationsauthor #8
P664: GRADING QUALITY OF EVIDENCE AND STRENGTH OF RECOMMENDATIONS FOR THE TREATMENT OF RELAPSED/REFRACTORY CLL.
20220 citationsauthor #10
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials
202213 citationsauthor #28
Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting
202214 citationsauthor #7
Clonal Hematopoiesis: Exploiting Molecular Landscape of Multiple Myeloma Patients for Choosing the Most Appropriate Therapeutic Strategy
20221 citationsauthor #9
Belantamab Mafodotin in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received at Least One Proteasome Inhibitor, One Immunomodulatory Agent and One Anti-CD38 Monoclonal Antibody: A Retro-Prospective Italian Observational Study
20225 citationsauthor #4
P564: FINAL RESULTS OF THE QOLESS AZA-AMLE RANDOMIZED TRIAL TO EVALUATE THE EFFICACY OF 5-AZA FOR POST-REMISSION THERAPY OF ACUTE MYELOID LEUKEMIA IN ELDERLY PATIENTS
20220 citationsauthor #3
Network meta‐analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant
20228 citationsauthor #15
Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic Syndromes
20223 citationsauthor #11
In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection
20228 citationsauthor #19
P1288: ALTERED AMINO ACID HOMEOSTASIS CAN ELICIT AN ADAPTIVE RESPONSE VIA UPREGULATION OF UFMYLATION IN HODGKIN LYMPHOMA
20221 citationsauthor #11
S136: CONSTITUTIVE VLA-4 ACTIVATION IN CHRONIC LYMPHOCYTIC LEUKEMIA. THE OTHER SIDE OF BCR AUTONOMOUS SIGNALING.
20220 citationsauthor #15
TLR4 Signaling and Heme Oxygenase-1/Carbon Monoxide Pathway Crosstalk Induces Resiliency of Myeloma Plasma Cells to Bortezomib Treatment
202215 citationsauthor #15
Arginine Deprivation in Microenvironment Makes Multiple Myeloma Resistant to Proteasome Inhibitors Via Increased Lactate Release and Metabolic Rewiring
20222 citationsauthor #16
P731: INTERPLAY BETWEEN INFLAMMATION AND EPIGENETICS IN TUMOR REPROGRAMMING OF MESENCHYMAL STROMAL CELLS (MSCS) IN MYELODYSPLASTIC SYNDROMES (MDS)
20220 citationsauthor #17
PB2279: REDUCED ABSOLUTE COUNT OF MONOCYTES IN PATIENTS CARRYING HEMATOLOGICAL NEOPLASMS AND SARS-COV2 BREAKTHROUGH INFECTION
20220 citationsauthor #13
Acquired hemophilia A following COVID-19 vaccination – The importance of prompt diagnosis: A case report
20227 citationsauthor #7
Management of infectious risk of daratumumab therapy in multiple myeloma: a consensus-based position paper from an ad hoc Italian expert panel.
202214 citationsauthor #4
P870: DEFINING A NOVEL FUNCTION FOR THE POST-TRANSLATIONAL MODIFICATION UFMYLATION IN THE ADAPTIVE RESPONSE TO ARGININE DEPRIVATION IN MULTIPLE MYELOMA
20220 citationsauthor #10
Therapeutic innovation for multi-resistant candidemics: Synergy of isavuconazole and caspofungin association
20212 citationsauthor #6
Safety and Effectiveness of Idelalisib in Patients with Double-Refractory Follicular Lymphoma: A Pan-European Cohort of 242 Patients
20211 citationsauthor #5
Venetoclax-Rituximab Treatment of Relapsed/Refractory CLL During the COVID-19 Pandemic: A Real-Life Experience in Selected Central-Southern Italian Regions
20212 citationsauthor #6
Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML
202144 citationsauthor #23
Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score
202115 citationsauthor #19
Use of Emicizumab in Patients with Hemophilia a with and without Inhibitors: A Single Center Experience
20213 citationsauthor #5
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts
202114 citationsauthor #12
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network
202118 citationsauthor #41
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
202120 citationsauthor #11
A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol
202156 citationsauthor #8
Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?
202126 citationsauthor #10
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia
20219 citationsauthor #13
Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey
202114 citationsauthor #18
Effectiveness of ibrutinib as first‐line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab‐bendamustine: Results of study on 486 cases outside clinical trials
20213 citationsauthor #42
Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy.
20211 citationsauthor #6
A Novel System for Semiautomatic Sample Processing in Chronic Myeloid Leukaemia: Increasing Throughput without Impacting on Molecular Monitoring at Time of SARS-CoV-2 Pandemic
20211 citationsauthor #11
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients
20218 citationsauthor #41
CXCL12/CXCR4 Axis Drives Mitochondrial Trafficking in Tumor Myeloma Microenvironment
20210 citationsauthor #17
Validation of the Alternative International Prognostic Score‐E (AIPS‐E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O‐CLL1‐GISL protocol
20215 citationsauthor #10
Role of Serum Free Light Chain Assay in Relapsed/Refractory Multiple Myeloma. A Real-Life Unicentric Retrospective Study
20215 citationsauthor #9
CD123 Is Consistently Expressed on NPM1-Mutated AML Cells
202131 citationsauthor #11
Phylogenetic analysis in the clinical risk management of an outbreak of Hepatitis C Virus infection among transfused thalassemia patients in Italy.
20214 citationsauthor #12
Assessment of the 4‐factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study
202114 citationsauthor #39
Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study
20215 citationsauthor #26
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases
202113 citationsauthor #40
Immune-mediated thrombotic thrombocytopenic purpura following administration of Pfizer-BioNTech COVID-19 vaccine
202117 citationsauthor #7
Dissecting the Adaptive Response to Arginine Deprivation in Hodgkin Lymphoma
20211 citationsauthor #14
Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
202118 citationsauthor #29
Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over
20212 citationsauthor #9
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database
202122 citationsauthor #15
Lenalidomide and Pomalidomide Improve Function and Induce FcγRI/CD64 in Multiple Myeloma Neutrophils
20213 citationsauthor #8
Combined Inhibition of Bcl2 and Bcr-Abl1 Exercises Anti-Leukemia Activity but Does Not Eradicate the Primitive Leukemic Cells
202111 citationsauthor #10
Hemophagocytic Syndrome in a Patient with ALL: Morphology Still Matters
20212 citationsauthor #5
INO-CD22: A Multi-Center, Real-Life Study on Inotuzumab-Ozogamicin Safety and Effectiveness in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
20211 citationsauthor #4

TIMELINE

1982 5 citations

1984 13 citations

1985 1 citations

1986 0 citations

1987 1 citations

1991 124 citations

1992 0 citations

1995 6 citations

1997 6 citations

1998 21 citations

2000 42 citations

2001 119 citations

2002 823 citations

2003 289 citations

2004 298 citations

2005 237 citations

2006 240 citations

2007 1,571 citations

2008 355 citations

2009 1,327 citations

2010 856 citations

2011 2,084 citations

2012 527 citations

2013 1,254 citations

2014 1,645 citations

2015 517 citations

2016 741 citations

2017 336 citations

2018 533 citations

2019 895 citations

2020 677 citations

2021 477 citations

2022 257 citations

2023 154 citations

2024 3 citations

F. Di Raimondo

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT